

October 22, 2019



## **Artelo Biosciences to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference**

LA JOLLA, Calif., Oct. 22, 2019 (GLOBE NEWSWIRE) -- [Artelo Biosciences, Inc. \(NASDAQ: ARTL\)](#), a clinical stage biopharmaceutical company developing therapeutics that modulate the endocannabinoid system, today announced that it will be presenting at the Dawson James Securities 5th Annual Small Cap Growth Conference being held on October 28-29, 2019 at the Wyndham Grand Hotel in Jupiter, Florida.

Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences, is scheduled to present on Tuesday, October 29<sup>th</sup> at 11:20 a.m. Eastern Time, in Track 2 - Preserve Ballroom B, with one-on-one meetings to be held throughout the conference.

### **About Dawson James Securities**

Dawson James Securities, Inc., a member of FINRA/SIPC, is a full-service investment bank headquartered in Boca Raton, FL. <http://www.dawsonjames.com>.

### **About Artelo Biosciences**

Artelo Biosciences, Inc. is a San Diego-based biopharmaceutical company dedicated to the development and commercialization of proprietary therapeutics targeting the endocannabinoid system. Artelo is rapidly advancing a portfolio of broadly applicable product candidates designed to address significant unmet needs in multiple diseases and conditions, including anorexia, cancer, pain, and inflammation. Led by proven biopharmaceutical executives collaborating with highly respected researchers and technology experts, the Company applies leading edge scientific, regulatory, and commercial discipline to develop high-impact therapies. More information is available at [www.artelobio.com](http://www.artelobio.com) and Twitter: [@ArteloBio](https://twitter.com/ArteloBio).

### **Investor Relations Contact:**

Crescendo Communications, LLC

Tel: 212-671-1020

Email: [ARTL@crescendo-ir.com](mailto:ARTL@crescendo-ir.com)



Source: Artelo Biosciences